Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety study of linerixibat in cholestatic pruritus associated with primary biliary cholangitis
jRCT2080225120Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2020
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of linerixibat in primary biliary cholangitis (PBC) and cholestatic pruritus, sponsored by GSK. Started Mar 2020; status: completed.
02
Drugs
linerixibat
03
Conditions
primary biliary cholangitis (PBC)cholestatic pruritus
Beyond the preview
Go deeper on jRCT2080225120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225120.